3SBio Inc (1530 HK): Hair Product Acts as the Savior; Marginal Growth of Flagship Drug

Alopecia drug Mandi recorded revenue growth of 40%+ in 1H22. With sound financial profile, strong portfolio of market leading drugs, and rich pipeline, 3SBio is an attractive investment idea.

SUMMARY

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

• Unlimited Research Summaries
• Personalised Alerts
• Custom Watchlists
• Company Data & News
• Events & Webinars

Trusted by:

SMARTKARMA PREVIEW PASS

Sign Up with LinkedIn

or

First NameLast nameEmail

Sign Up with EmailBy signing up, you agree to our
Terms of Use and Privacy Policy.

Trusted by:

Already have an account? Sign In Now

---